US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Lakeshore Acquisition I Corp. - Ordinary Shares
(NQ:
LAAA
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Dec 6, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lakeshore Acquisition I Corp. - Ordinary Shares
ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices
December 06, 2022
From
ProSomnus Sleep Technologies, Inc.
Via
GlobeNewswire
ProSomnus® Announces FDA 510(k) Clearance for ProSomnus EVO™ [PH] Sleep and Snore Device
November 02, 2022
From
ProSomnus Sleep Technologies, Inc.
Via
GlobeNewswire
EXCLUSIVE: SPAC Merger Partner ProSomnus' Sleep & Snore Device Scores FDA Approval
↗
November 02, 2022
Soon to be listed, ProSomnus has received FDA 510(k) clearance for its flagship product, ProSomnus EVO [PH] Sleep and Snore Device. ProSomnus EVO is a less invasive Precision Oral Appliance Therapy...
Via
Benzinga
ProSomnus® Sleep Technologies to Participate at the Oppenheimer Private Company Showcase
October 05, 2022
From
ProSomnus Sleep Technologies, Inc.
Via
GlobeNewswire